Provide initial data from the 50 mg dose open label study and adolescent PK run-in study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 14 Aug 2025
- Due
- 30 Sep 2025
- Delivered
- 29 Sep 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Initial data from the 50 mg dose in the open label study and the adolescent PK run-in study planned for program update in September 2025”
What we found
Evidence strength B What the grades mean
Larimar announced initial 50 mg open label study and adolescent PK run-in data on September 29, 2025, within the stated September 2025 deadline.
-
B Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study
“Increases in skin FXN levels with short- and long-term daily nomlabofusp; Exposure and PK in adolescents spanning 12 to 17 years of age (n = 14, 5 on placebo) were similar to adults on 50 mg of nomlabofusp.” ✓ confirmed on the page
-
D Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study
“Informative Adolescent PK Run-In Data: Adolescents 12 to 17 years of age received a weight-based equivalent of 50 mg for 7 days. Exposure and PK in adolescents spanning 12 to 17 years of age (n = 14, 5 on placebo) were similar to adults on 50 mg of nomlabofusp.”
Checked 8 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Provide
- Deliverable
- Initial clinical trial data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-LRMR-003060 · Corrections policy